Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA; Massachusetts Institute of Technology, Cambridge, MA, USA.
Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Cell Rep. 2023 Nov 28;42(11):113292. doi: 10.1016/j.celrep.2023.113292. Epub 2023 Oct 28.
The reduced effectiveness of COVID-19 vaccines due to the emergence of variants of concern (VOCs) necessitated the use of vaccine boosters to bolster protection against disease. However, it remains unclear how boosting expands protective breadth when primary vaccine platforms are distinct and how boosters containing VOC spike(s) broaden humoral responses. Here, we report that boosters composed of recombinant spike antigens of ancestral (prototype) and Beta VOCs elicit a robust, pan-VOC, and multi-functional humoral response in non-human primates largely independent of the primary vaccine series platform. Interestingly, Beta-spike-containing boosters stimulate immunoglobulin A (IgA) with a greater breadth of recognition in protein-primed recipients when administered with adjuvant system 03 (AS03). Our results highlight the utility of a component-based booster strategy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for broad humoral recognition, independent of primary vaccine series. This is of high global health importance given the heterogeneity of primary vaccination platforms distributed.
由于关注的变异株(VOCs)的出现,COVID-19 疫苗的效力降低,因此需要使用疫苗加强针来增强对疾病的保护。然而,当主要疫苗平台不同时,加强针如何扩大保护广度,以及含有 VOC 刺突(s)的加强针如何扩大体液反应仍然不清楚。在这里,我们报告说,由原始(原型)和 Beta VOC 的重组刺突抗原组成的加强针在非人类灵长类动物中引发了强大的、泛 VOC 和多功能的体液反应,主要独立于初级疫苗系列平台。有趣的是,当与佐剂系统 03(AS03)联合使用时,含有 Beta 刺突的加强针在蛋白引发的受者中刺激免疫球蛋白 A(IgA)具有更大的识别广度。我们的结果强调了基于成分的 SARS-CoV-2 加强针策略的实用性,用于广泛的体液识别,独立于初级疫苗系列。鉴于分布的初级接种平台的异质性,这对全球健康具有重要意义。